Market Overview

Recent Stories

Central Garden & Pet Co (NASDAQ: CENT), which distributes products for the lawn and garden and pet supplies market, has an attractive risk/reward profile at current levels, according to an analyst at KeyBanc Capital Markets.

The Benzinga Global Fintech Awards are a yearly showcase of the best and brightest in fintech. In preparation for its biggest installment yet in May 2018, we're profiling the companies competing for the BZ Awards.

Apple Inc. (NASDAQ: AAPL) shares fell marginally but sharply Tuesday afternoon when JPMorgan reported findings suggesting weakening iPhone X orders.

Shares of Inter Parfums, Inc. (NASDAQ: IPAR), which operated fragrance business, are likely to be weighed down by valuation and a lack of fundamental catalysts, according to an analyst at KeyBanc.

Toward the end of trading Tuesday, the Dow traded down 0.01 percent to 26,214.27 while the NASDAQ gained 0.67 percent to 7,457.91. The S&P also rose, gaining 0.24 percent to 2,839.73.

There are certainly plenty of things to criticize about President Donald Trump’s first year in office, but stock market performance isn't one of them. Trump has repeatedly taken credit for the huge bull market that continued during his first year at the White House.

After being on the sidelines for more than 18 months on network security vendor Palo Alto Networks Inc (NYSE: PANW), Deutsche Bank has moved in.

The Analyst

Deutsche Bank analyst Karl Keirstead upgraded shares of Palo Alto from Hold to Buy, and upped his price target from $160 to $180.

Adobe Systems Incorporated (NASDAQ: ADBE) shares peaked as much as 6.4 percent after hours Monday on positive guidance and news of the CFO’s retirement.

One analyst firm thinks the market’s underreacting.

Benzinga is proud to introduce the Benzinga Women's Wealth Forum, a space where women can learn how to empower themselves through financial technology and be inspired by the stories of powerful women in finance.

After a lull in 2016 and 2017, M&A activity seems to be picking up pace in 2018.. The action seems to be even more brisk in the pharma sector, as companies attempt to give depth to their product portfolio and mitigate any potential revenue hit from key drugs falling off patents in the near- to medium-term.